Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.62 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.62 |
| ▸ | FLT1 | P17948 | 1/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368901 | 0.91 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL5548828 | 0.91 | PDGFRB (0.60) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL1721029 | 0.91 | PDGFRB (0.68) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL4097915 | 0.90 | PDGFRB (0.55) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL2897709 | 0.90 | PDGFRB (0.67) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12604704 | 0.88 | PDGFRB (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL14993469 | 0.87 | PDGFRB (0.59) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL20594284 | 0.87 | PDGFRB (0.59) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL19389743 | 0.87 | PDGFRB (0.52) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL12190692 | 0.85 | PDGFRB (0.51) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010489-B1 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| EP-2010490-B1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-7880010-B2 | form 1 of crystalline free base of biphenyl-2-ylcarbamic acid 1-[2-(4-{[(R)-2-(3-formylamino-4-hydroxyphenyl)-2-hydroxyethylamino]methyl}-2,5-dimethylphenylcarbamoyl)ethyl]piperidin-4-yl ester; useful for treating pulmonary disorders, such as asthma and chronic obstructive pulmonary disease | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687521-B2 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| CN-101426764-A | Having beta2Dialkylphenyl compounds with adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE INC (US) | 2009-05-06 | — | — | CN | disclosed |
| CN-101426765-A | Crystalline forms of dimethylphenyl compounds | THERAVANCE INC (US) | 2009-05-06 | — | — | CN | disclosed |
| US-7524965-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-2010489-A2 | DIALKYLPHENYL COMPOUNDS HAVING 2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | Theravance, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2010490-A2 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | Theravance, Inc. (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007127297-A2 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | THERAVANCE, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127196-A2 | DIALKYLPHENYL COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249674-A1 | Crystalline forms of a dimethylphenyl compound | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | PDGFRB 1056/4885FGFR1 255/4885PDGFRA 1212/4885 |
| US-20110086881-A1 | CRYSTALLINE FORMS OF A DIMETHYLPHENYL COMPOUND | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, PKD1 | PDGFRB 1056/4885FGFR1 255/4885PDGFRA 1212/4885 |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | PDGFRB 519/4885FGFR1 895/4885PDGFRA 707/4885 |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | PDGFRB 519/4885FGFR1 895/4885PDGFRA 707/4885 |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRB1, ADRA2C | PDGFRB 519/4885FGFR1 895/4885PDGFRA 707/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | PDGFRB 1271/4885FGFR1 2442/4885PDGFRA 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.